Prostate cancer is affecting the prostate glands in the male. Prostate cancer is a common cancer following skin cancer in the male. Some common determinants responsible for the start of prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and also treat prostate cancer and helps radiologists to conclude the stage of cancer. US prostate cancer nuclear medicine diagnostics market is driven by factors such as the rising prevalence of prostate cancer, and the growth of innovative radiopharmaceuticals plays a vital role in the growth of the radiopharmaceuticals market. However, strict guidelines for storage, production, & use of radiopharmaceuticals is likely to obstruct the growth of the US prostate cancer nuclear medicine diagnostics market during the forecast period.
Register for a free trial today and gain instant access to our market research reports at
Rising Prevalence of Prostate Cancer
Prostate cancer (PCa) is the fourth common cancer across the US in terms of occurrence. The rising prevalence of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. For instance, according to GLOBOCAN, in 2018, there were around 2,129,118 cases of cancer in the US. Among these cases, about 10% were prostate cancer, i.e., 212,783 incidences in 2018. Moreover, the country reported 28,705 deaths due to cancer. The organization has estimated the cases of prostate cancer to reach above 737,463 in the next five years. After skin cancer, prostate cancer is the most common cancer in the American male. As per the data of the American Cancer Society, 2020, it was estimated that prostate cancer would be around 191,930 and approximately 33,330 deaths from prostate cancer in the United States for 2020. Prostate cancer is more likely to grow in older adults. Almost 6 cases in 10 are identified in men who are 65 or more.
Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the US prostate cancer nuclear medicine diagnostics market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name.
US Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
US Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
- Blue Earth Diagnostics Limited
- Progenics Pharmaceuticals, Inc.
- Telix Pharmaceuticals Ltd.
- NCM-USA LLC
- ABX Advanced Biochemical Compounds GmbH
- Jubilant Radiopharma
- Lantheus Medical Imaging, Inc.
- Advanced Accelerator Applications (Novartis AG)
Business Market Insights provides affordable subscription with pay as per requirement at https://www.businessmarketinsights.com/TIPRE00008334/checkout/basic/single/monthly/
(30-day subscription plans prove to be very cost-effective with no compromise on the quality of reports)
Benefits with Business Market Insights
- One Stop Platform to All the Market Insight Needs
- Avoid Long Purchase Procedures
- Fast and Easy Access
- Cloud-Based Platform
- News Updates
- Ask the Analyst Support
- Pay Monthly Subscription and Access All You Want
- No Compulsion for Yearly Subscription
- Reports Read or Download Access
- Monthly New Reports Added
- Affordable Product, Pay as Per Requirement
About Business Market Insights
Based in New York, Business Market Insights is a one-stop destination for in-depth market research reports from various industries including Technology, Media & Telecommunications, Semiconductor & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Healthcare IT, Manufacturing & Construction, Medical Device, and Chemicals & Materials. The clients include corporate and academic professionals, consulting, research firms, PEVC firms, and professional services firms.
For Subscription contact
Business Market Insights